GCM
ALNY icon

Goldstream Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Goldstream Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,096
Closed -$3.07M – 16
2021
Q4 		$3.07M Buy
+18,096
New +$3.36M 0.75% 13

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldstream Capital Management's ALNY Position: Q1 2022 in Review

Goldstream Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 18,096 shares — an estimated $3.07M sold.

Goldstream Capital Management first reported a position in ALNY in Q4 2021 and held it in 1 quarter. The position peaked at $3.07M in Q4 2021. 443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Goldstream Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 18,096 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $3.07M.
  • Goldstream Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Goldstream Capital Management's Alnylam Pharmaceuticals position peaked at $3.07M in Q4 2021.
  • 443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Goldstream Capital Management's 13F filing for Q1 2022, filed 13 May 2022.